keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium 90

keyword
https://www.readbyqxmd.com/read/28317063/prognostic-value-of-pretreatment-diffusion-weighted-magnetic-resonance-imaging-for-outcome-prediction-of-colorectal-cancer-liver-metastases-undergoing-90y-microsphere-radioembolization
#1
Frederic Carsten Schmeel, Birgit Simon, Julian Alexander Luetkens, Frank Träber, Carsten Meyer, Leonard Christopher Schmeel, Amir Sabet, Samer Ezziddin, Hans Heinz Schild, Dariusch Reza Hadizadeh
PURPOSE: To investigate the clinical potential of pretreatment apparent diffusion coefficient (ADC) on diffusion-weighted magnetic resonance imaging (DWI) for therapy response and outcome prediction in patients with liver-predominant metastatic colorectal cancer (CRC) undergoing radioembolization with (90)Yttrium-microspheres (90Y-RE). METHODS: Forty-six consecutive patients with unresectable CRC liver metastases underwent standardized clinical DWI on a 1.5 T MR scanner prior to and 4-6 weeks after 90Y-RE...
March 19, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28303300/consequences-of-radiopharmaceutical-extravasation-and-therapeutic-interventions-a-systematic-review
#2
REVIEW
Jochem van der Pol, Stefan Vöö, Jan Bucerius, Felix M Mottaghy
PURPOSE: Radiopharmaceutical extravasation can potentially lead to severe soft tissue damage, but little is known about incidence, medical consequences, possible interventions, and effectiveness of these. The aims of this study are to estimate the incidence of extravasation of diagnostic and therapeutic radiopharmaceuticals, to evaluate medical consequences, and to evaluate medical treatment applied subsequently to those incidents. METHODS: A sensitive and elaborate literature search was performed in Embase and PubMed using the keywords "misadministration", "extravasation", "paravascular infiltration", combined with "tracer", "radionuclide", "radiopharmaceutical", and a list of keywords referring to clinically used tracers (i...
March 16, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28300366/internal-dosimetry-for-radioembolization-therapy-with-yttrium-90-microspheres
#3
Maryam Fallahpoor, Mehrshad Abbasi, Ali Asghar Parach, Faraz Kalantari
The absorbed doses in the liver and adjacent viscera in Yttrium-90 radioembolization therapy for metastatic liver lesions are not well-documented. We sought for a clinically practical way to determine the dosimetry of this advent treatment. Six different female XCAT BMIs and seven different male XCAT BMIs were generated. Using Monte Carlo GATE code simulation, the total of 100MBq (90) Y was deposited uniformly in the source organ, liver. Self-irradiation and absorbed doses in lung, kidney and bone marrow were calculated...
March 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28299645/new-concepts-in-embolotherapy-of-hcc
#4
REVIEW
F Pesapane, N Nezami, F Patella, J F Geschwind
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related deaths worldwide with rapidly growing incidence rates in the USA and Europe. Despite improving surveillance programs, most patients are diagnosed at intermediate to advanced stages and are no longer amenable to curative therapies, such as ablation, surgical resection and liver transplantation. For such patients, catheter-based image-guided embolotherapies such as transarterial chemoembolization (TACE) represent the standard of care and mainstay therapy, as recommended and endorsed by a variety of national guidelines and staging systems...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28291008/the-efficacy-of-yttrium-90-radiosynovectomy-in-patients-with-camptodactyly-arthropathy-coxa-vara-pericarditis-syndrome
#5
Sulaiman Mohammed Al-Mayouf, Nora Almutairi, Khalid Alismail
OBJECTIVE: Camptodactyly-arthropathy-coxa-vara-pericarditis (CACP) syndrome is an autosomal recessive disorder caused by mutations in PRG4 gene that encodes for proteoglycan 4, the main lubricant for joints and tendon surfaces. It is a non-inflammatory arthropathy, characterized by joint effusions and synovial hypertrophy. So far, there is no effective treatment for this disorder. To evaluate the effectiveness of yttrium-90 radiosynovectomy in arthropathy of patients with CACP syndrome...
February 5, 2017: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/28288710/possible-novel-agents-in-marginal-zone-lymphoma
#6
REVIEW
Pier Luigi Zinzani, Alessandro Broccoli
Efficacy, safety and mechanisms of action of novel agents in marginal zone lymphoma patients, both with a nodal and extranodal presentation, are reviewed. Data on lenalidomide, bortezomib and (90)yttrium-ibrutumomab tiuxetan are obtained from trials specifically designed for patients affected by marginal zone lymphoma and with various disease presentations. The role of targeted agents, such as obinutuzumab, ibrutinib and idelalisib, and of some very new drugs (venetoclax, copanlisib, ublituximab and TGR-1202) is also discussed, taking into account the most relevant experiences in patients with indolent non-Hodgkin's lymphomas...
March 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/28282068/surgical-treatment-and-optical-coherence-tomographic-evaluation-for-accidental-laser-induced-full-thickness-macular-holes
#7
Y Qi, Y Wang, Q You, F Tsai, W Liu
PurposeTo report OCT appearance and surgical outcomes of full-thickness macular holes (MHs) accidentally caused by laser devices.Patients and methodsThis retrospective case series included 11 eyes of 11 patients with laser-induced MHs treated by pars plana vitrectomy, internal limiting membrane (ILM) peeling, and gas or silicone oil tamponade. Evaluations included a full ophthalmic examination, macular spectral-domain optical coherence tomography (SD-OCT), and fundus photography. Main outcome measures is MH closure and final visual acuity; the secondary outcome was the changes of retinal pigment epithelium and photoreceptor layer evaluated by sequential post-operative SD-OCT images...
March 10, 2017: Eye
https://www.readbyqxmd.com/read/28267593/phase-ii-study-of-yttrium-90-ibritumomab-tiuxetan-plus-high-dose-beam-for-non-hodgkin-lymphoma-the-role-of-histology
#8
Amrita Y Krishnan, Joycelynne Palmer, Auayporn P Nademanee, Robert Chen, Leslie L Popplewell, Ni-Chun Tsai, James F Sanchez, Jennifer Simpson, Ricardo Spielberger, Dave Yamauchi, Stephen J Forman
Standard-dose (90)yttrium-ibritumomab tiuxetan (0.4 mci/kg) (Zevalin) together with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) (Z-BEAM) has been shown to be a well-tolerated autologous hematopoietic stem cell transplantation (autoHCT) preparative regimen for non-Hodgkin lymphoma. We report the outcomes of a single-center, single-arm phase II trial of Z-BEAM conditioning in high-risk CD20(+) non-Hodgkin lymphoma histologic strata: diffuse large B cell (DLBCL), mantle cell (MCL), follicular (FL), and transformed (TF)...
March 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28261595/commentary-on-the-article-entitled-hepatocellular-carcinoma-with-macrovascular-invasion-treated-with-yttrium-90-radioembolization-prior-to-transplantation
#9
Wan Yee Lau
No abstract text is available yet for this article.
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28261594/hepatocellular-carcinoma-with-macrovascular-invasion-treated-with-yttrium-90-radioembolization-prior-to-transplantation
#10
Giovanni Battista Levi Sandri, Giuseppe Maria Ettorre, Marco Colasanti, Edoardo De Werra, Gianluca Mascianà, Daniele Ferraro, Giovanni Tortorelli, Rosa Sciuto, Pierleone Lucatelli, Giuseppe Pizzi, Ubaldo Visco-Comandini, Giovanni Vennarecci
BACKGROUND: Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. According to the staging system of the Barcelona Clinic Liver Cancer (BCLC), patients with macrovascular invasion are staged as BCLC-C. This paper comprises a presentation of the results following application of the procedure. METHODS: From January 2002 to December 2015, 367 patients were transplanted at the San Camillo Hospital Center...
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28261591/intra-arterial-embolotherapy-for-intrahepatic-cholangiocarcinoma-update-and-future-prospects
#11
REVIEW
Lynn Jeanette Savic, Julius Chapiro, Jean-François H Geschwind
Intrahepatic cholangiocarcinoma (ICC) is a rare disease and carries a poor prognosis with surgery remaining the only curative treatment option. However, due to the late presentation of symptoms and close proximity of the tumors to central hepatic structures, only about 30% of patients are classified eligible to resection. As for palliative approaches, ICC constitutes a possible indication for loco-regional therapies (LRT). As such, intra-arterial therapies (IAT) are reported to be feasible, safe and effective in inducing tumor response in unresectable ICC...
February 2017: Hepatobiliary Surgery and Nutrition
https://www.readbyqxmd.com/read/28260927/intrahepatic-cholangiocarcinoma-current-perspectives
#12
REVIEW
Stefan Buettner, Jeroen LA van Vugt, Jan Nm IJzermans, Bas Groot Koerkamp
Intrahepatic cholangiocarcinoma (ICC) is the second most common malignancy arising from the liver. ICC makes up about 10% of all cholangiocarcinomas. It arises from the peripheral bile ducts within the liver parenchyma, proximal to the secondary biliary radicals. Histologically, the majority of ICCs are adenocarcinomas. Only a minority of patients (15%) present with resectable disease, with a median survival of less than 3 years. Multidisciplinary management of ICC is complicated by large differences in disease course for individual patients both across and within tumor stages...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28238581/correlation-of-technetium-99m-macroaggregated-albumin-and-yttrium-90-glass-microsphere-biodistribution-in-hepatocellular-carcinoma-a-retrospective-review-of-pretreatment-single-photon-emission-ct-and-posttreatment-positron-emission-tomography-ct
#13
Paul Haste, Mark Tann, Scott Persohn, Thomas LaRoche, Vasantha Aaron, Thibault Mauxion, Nikhil Chauhan, Matthew R Dreher, Matthew S Johnson
PURPOSE: To evaluate whether technetium-99 ((99m)Tc)-labeled macroaggregated albumin (MAA) can predict subsequent yttrium-90 ((90)Y) distribution and imaging response in patients with hepatocellular carcinoma (HCC). MATERIALS: Retrospective review was performed of records of 83 patients with HCC who underwent (90)Y glass microsphere radioembolization with (99m)Tc-MAA single photon emission computed tomography (SPECT) and (90)Y positron emission tomography (PET)/CT between January 2013 and December 2014...
February 23, 2017: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/28202430/vespro-an-individual-patient-data-prospective-meta-analysis-of-selective-internal-radiation-therapy-versus-sorafenib-for-advanced-locally-advanced-or-recurrent-hepatocellular-carcinoma-of-the-sarah-and-sirvenib-trials
#14
Val Gebski, Emma Gibbs, Mihir Gandhi, Gilles Chatellier, Aurelia Dinut, Helena Pereira, Pierce Kh Chow, Valérie Vilgrain
BACKGROUND: Untreated advanced hepatocellular carcinoma (HCC) has an overall poor prognosis. Currently there are 2 ongoing prospective randomized controlled trials that are evaluating the efficacy and safety of sorafenib and selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres in patients with advanced HCC. The SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma (SARAH; 459 patients) trial is being performed in Europe and the SIRt VErsus SorafeNIB (SIRveNIB; 360 patients) trial in the Asia Pacific region...
February 15, 2017: JMIR Research Protocols
https://www.readbyqxmd.com/read/28197686/pre-therapeutic-factors-for-predicting-survival-after-radioembolization-a-single-center-experience-in-389-patients
#15
K J Paprottka, F Schoeppe, M Ingrisch, J Rübenthaler, N N Sommer, E De Toni, H Ilhan, M Zacherl, A Todica, P M Paprottka
PURPOSE: To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). METHODS: We retrospectively analyzed the pre-therapeutic characteristics (sex, age, tumor entity, hepatic tumor burden, extrahepatic disease [EHD] and liver function [with focus on bilirubin and cholinesterase level]) of 389 consecutive patients with various refractory liver-dominant tumors (hepatocellular carcinoma [HCC], cholangiocarcinoma [CCC], neuroendocrine tumor [NET], colorectal cancer [CRC] and metastatic breast cancer [MBC]), who received Y-90 radioembolization for predicting survival...
February 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28187357/a-simple-thick-target-for-production-of-89-zr-using-an-11mev-cyclotron
#16
Jeanne M Link, Kenneth A Krohn, Matthew J O'Hara
The growing interest but limited availability of (89)Zr for PET led us to test targets for the (89)Y(p,n) reaction. The goal was an easily constructed target for an 11MeV Siemens cyclotron. Yttrium foils were tested at different thicknesses, angles and currents. A 90° foil tolerated 41µA without damage and produced ~800 MBq/h, >20mCi, an amount adequate for radiochemistry research and human doses in a widely available accelerator. This method should translate to higher energy cyclotrons.
January 30, 2017: Applied Radiation and Isotopes
https://www.readbyqxmd.com/read/28182580/internal-dosimetry-with-the-monte-carlo-code-gate-validation-using-the-icrp-icru-female-reference-computational-model
#17
Daphnée Villoing, Sara Marcatili, Marie-Paule Garcia, Manuel Bardiès
The purpose of this work was to validate GATE-based clinical scale absorbed dose calculations in nuclear medicine dosimetry. GATE (version 6.2) and MCNPX (version 2.7.a) were used to derive dosimetric parameters (absorbed fractions, specific absorbed fractions and S-values) for the reference female computational model proposed by the International Commission on Radiological Protection in ICRP report 110. Monoenergetic photons and electrons (from 50 keV to 2 MeV) and four isotopes currently used in nuclear medicine (fluorine-18, lutetium-177, iodine-131 and yttrium-90) were investigated...
March 7, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28154910/value-of-tumor-stiffness-measured-with-mr-elastography-for-assessment-of-response-of-hepatocellular-carcinoma-to-locoregional-therapy
#18
Sonja Gordic, Jad Bou Ayache, Paul Kennedy, Cecilia Besa, Mathilde Wagner, Octavia Bane, Richard L Ehman, Edward Kim, Bachir Taouli
PURPOSE: The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA). MATERIAL AND METHODS: This retrospective study was IRB-approved and the requirement for informed consent was waived...
February 2, 2017: Abdominal Radiology
https://www.readbyqxmd.com/read/28132407/single-institution-experience-of-radioembolization-with-yttrium-90-microspheres-for-unresectable-metastatic-neuroendocrine-liver-tumors
#19
Zhongzhi Jia, Ricardo Paz-Fumagalli, Gregory Frey, David M Sella, J Mark McKinney, Weiping Wang
PURPOSE: To assess the effectiveness of yttrium-90 ((90) Y) microspheres for the treatment of unresectable metastatic liver neuroendocrine tumors (NET). METHODS: From February 2006 to September 2015, 36 patients (19 male and 17 female, age, 63.6 ± 9.4 years) who underwent (90) Y therapy for unresectable liver metastases of NET were included and analyzed retrospectively. All patients received a variety of treatments prior to (90) Y therapy. The radiological response, symptoms improvement of carcinoid syndrome, tumor marker changes, complications, side effects/toxicity, survival and factors related to survival were evaluated and analyzed...
January 29, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28121731/differences-in-radiation-activity-between-glass-and-resin-90y-microspheres-in-treating-unresectable-hepatic-cancer
#20
Trent James, Jacqueline Hill, Thomas Fahrbach, Zachary Collins
The purpose of this study was to compare the difference in prescribed radiation activity between glass and resin yttrium-90 (Y) microspheres for radioembolization of unresectable hepatocellular carcinoma (HCC) or liver metastases at a tertiary care teaching institution. The authors performed a retrospective analysis on 126 patients with primary HCC and hepatic metastatic disease from extrahepatic primary cancers who underwent radioembolization with glass or resin particles between 2008 and 2013 at their institution...
March 2017: Health Physics
keyword
keyword
8545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"